{"id":343231,"date":"2025-08-22T11:28:03","date_gmt":"2025-08-22T11:28:03","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-schrdinger\/"},"modified":"2025-08-22T11:28:03","modified_gmt":"2025-08-22T11:28:03","slug":"how-to-buy-schrdinger","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/","title":{"rendered":"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-343231","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Schr\u00f6dinger, Inc. (SDGR) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025-2030 yat\u0131r\u0131m stratejisi i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma rehberi ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Schr\u00f6dinger, Inc. (SDGR) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve 2025-2030 yat\u0131r\u0131m stratejisi i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma rehberi ile \u00f6\u011frenin."},"intro":"Yapay zeka destekli ila\u00e7 ke\u015ffinin gelece\u011fine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Schr\u00f6dinger, Inc. (SDGR), teknoloji ve sa\u011fl\u0131k hizmetlerinin kesi\u015fiminde b\u00fcy\u00fcleyici bir f\u0131rsat sunuyor. Bu hesaplamal\u0131 kimya \u00f6nc\u00fcs\u00fc, ila\u00e7 \u015firketlerinin yeni ila\u00e7lar ke\u015ffetme \u015feklini d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor ve ileri g\u00f6r\u00fc\u015fl\u00fc yat\u0131r\u0131mc\u0131lar i\u00e7in etkileyici bir b\u00fcy\u00fcme hikayesi olu\u015fturuyor. SDGR'nin neyi tetikledi\u011fini ve bu yenilik\u00e7i \u015firketi portf\u00f6y\u00fcn\u00fcze nas\u0131l ekleyebilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Yapay zeka destekli ila\u00e7 ke\u015ffinin gelece\u011fine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Schr\u00f6dinger, Inc. (SDGR), teknoloji ve sa\u011fl\u0131k hizmetlerinin kesi\u015fiminde b\u00fcy\u00fcleyici bir f\u0131rsat sunuyor. Bu hesaplamal\u0131 kimya \u00f6nc\u00fcs\u00fc, ila\u00e7 \u015firketlerinin yeni ila\u00e7lar ke\u015ffetme \u015feklini d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor ve ileri g\u00f6r\u00fc\u015fl\u00fc yat\u0131r\u0131mc\u0131lar i\u00e7in etkileyici bir b\u00fcy\u00fcme hikayesi olu\u015fturuyor. SDGR'nin neyi tetikledi\u011fini ve bu yenilik\u00e7i \u015firketi portf\u00f6y\u00fcn\u00fcze nas\u0131l ekleyebilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>Schr\u00f6dinger'in Mevcut Piyasa Konumunu Anlamak<\/h2> <p>22 A\u011fustos 2025 itibar\u0131yla Schr\u00f6dinger, Inc. (SDGR) hisseleri <strong>19,58 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor - bu, hem \u00f6nemli teknik g\u00f6stergelerin alt\u0131nda kritik bir fiyat noktas\u0131d\u0131r. Hisse senedi, 50 g\u00fcnl\u00fck hareketli ortalamas\u0131 olan 20,97 $ ve 200 g\u00fcnl\u00fck hareketli ortalamas\u0131 olan 21,82 $ seviyelerinin alt\u0131nda i\u015flem g\u00f6rerek ilgin\u00e7 bir kav\u015fakta bulunuyor.<\/p> <h3>Takip Edilmesi Gereken Kritik Kazan\u00e7 Tarihi<\/h3> <p>Takviminize <strong>12 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin - Schr\u00f6dinger'in 2025 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu \u00e7eyreklik a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur. Son kazan\u00e7lara bak\u0131ld\u0131\u011f\u0131nda:<\/p> <ul> <li><strong>6 A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 beklentileri a\u015ft\u0131; gelir 54,76 milyon $ (52,03 milyon $ tahminin \u00fczerinde) ve hisse ba\u015f\u0131na kazan\u00e7 (EPS) -0,59 $ (beklenen -0,83 $'dan daha iyi). Hisse senedi bu s\u00fcrpriz kazan\u00e7 sonras\u0131 pozitif ivme g\u00f6sterdi.<\/li> <li><strong>\u00d6nceki \u00e7eyrek<\/strong>: 2025 1. \u00e7eyrek gelir beklentiyi kar\u015f\u0131lad\u0131 ancak EPS beklentiyi kar\u015f\u0131lamad\u0131, bu da b\u00fcy\u00fcme a\u015famas\u0131ndaki biyoteknoloji \u015firketlerinde g\u00f6r\u00fclen volatiliteyi g\u00f6steriyor.<\/li> <\/ul> <p>Model, pozitif kazan\u00e7 s\u00fcrprizlerinin genellikle s\u00fcrd\u00fcr\u00fclebilir yukar\u0131 y\u00f6nl\u00fc ivme yaratt\u0131\u011f\u0131n\u0131, beklentilerin kar\u015f\u0131lanmamas\u0131n\u0131n ise k\u0131sa vadeli d\u00fczeltmeler ve ard\u0131ndan toparlanma ile sonu\u00e7land\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>Fiyat Performans Analizi: Son 6 Ay<\/h2> <p>Schr\u00f6dinger hisseleri son alt\u0131 ayda \u00f6nemli volatilite ya\u015fad\u0131; bu, hem piyasa duyarl\u0131l\u0131\u011f\u0131 de\u011fi\u015fimlerini hem de \u015firket \u00f6zelindeki geli\u015fmeleri yans\u0131t\u0131yor:<\/p> <table> <thead> <tr><th>D\u00f6nem<\/th><th>Fiyat Aral\u0131\u011f\u0131<\/th><th>Temel Etkenler<\/th><\/tr> <\/thead> <tbody> <tr><td>\u015eubat-Mart 2025<\/td><td>18-22 $<\/td><td>4. \u00e7eyrek kazan\u00e7 sonras\u0131 iyimserlik<\/td><\/tr> <tr><td>Nisan-May\u0131s 2025<\/td><td>17-20 $<\/td><td>Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fc bask\u0131s\u0131<\/td><\/tr> <tr><td>Haziran-Temmuz 2025<\/td><td>16-19 $<\/td><td>Maliyet azaltma duyurular\u0131<\/td><\/tr> <tr><td>A\u011fustos 2025<\/td><td>17-20 $<\/td><td>2. \u00e7eyrek kazan\u00e7 s\u00fcrprizi sonras\u0131 toparlanma<\/td><\/tr> <\/tbody> <\/table> <p>Hisse senedi genel olarak 19 $ seviyesinde konsolidasyon g\u00f6sterdi, %6,55 volatilite orta d\u00fczey fiyat dalgalanmalar\u0131n\u0131 i\u015faret ediyor. Son bir ayda i\u015flem g\u00fcnlerinin sadece %47'si pozitif oldu, bu da temel iyile\u015fmelere ra\u011fmen temkinli yat\u0131r\u0131mc\u0131 duyarl\u0131l\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p> <h2>Ad\u0131m Ad\u0131m: SDGR'nin Yat\u0131r\u0131m Potansiyelini Analiz Etmek<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Mali durumu g\u00f6zden ge\u00e7ir<\/td><td>Negatif EPS (-2,48) ancak g\u00fc\u00e7l\u00fc gelir b\u00fcy\u00fcmesi (+%15,7 Y\u0131ll\u0131k)<\/td><\/tr> <tr><td>2<\/td><td>\u0130la\u00e7 geli\u015ftirme hatt\u0131n\u0131 de\u011ferlendir<\/td><td>\u00dc\u00e7 klinik a\u015fama onkoloji program\u0131 ilerliyor<\/td><\/tr> <tr><td>3<\/td><td>Ortakl\u0131klar\u0131 takip et<\/td><td>150 milyon $ Novartis i\u015f birli\u011fi onay sa\u011fl\u0131yor<\/td><\/tr> <tr><td>4<\/td><td>Nakit pozisyonunu izle<\/td><td>Negatif nakit ak\u0131\u015f\u0131 dikkatli izleme gerektirir<\/td><\/tr> <tr><td>5<\/td><td>Sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131n\u0131 g\u00f6zlemle<\/td><td>Biyoteknoloji volatilitesi de\u011ferleme \u00e7arpanlar\u0131n\u0131 etkiler<\/td><\/tr> <\/tbody> <\/table> <h2>Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Kapsaml\u0131 analist de\u011ferlendirmeleri ve piyasa projeksiyonlar\u0131na dayanarak, beklenenler \u015funlard\u0131r:<\/p> <p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 21-23 $ aral\u0131\u011f\u0131 (mevcut fiyattan %7-17 art\u0131\u015f)<br> - %10-15 yaz\u0131l\u0131m gelir b\u00fcy\u00fcmesi rehberli\u011fi ile destekleniyor<br> - \u0130la\u00e7 hatt\u0131 ilerlemelerinden potansiyel kataliz\u00f6r<\/p> <p><strong>2026 Tahmini<\/strong>: 24-28 $ (y\u00fczde 22-43 b\u00fcy\u00fcme)<br> - Maliyet tasarruflar\u0131n\u0131n etkisiyle EPS'de iyile\u015fme bekleniyor<br> - Ek ortakl\u0131k duyurular\u0131 potansiyeli<\/p> <p><strong>2028 Projeksiyonu<\/strong>: 29-35 $ (y\u00fczde 48-79 de\u011fer art\u0131\u015f\u0131)<br> - Mevcut klinik programlar\u0131n olgunla\u015fmas\u0131<br> - Hesaplamal\u0131 ila\u00e7 ke\u015ffinde pazar pay\u0131n\u0131n geni\u015flemesi<\/p> <p><strong>2030 Uzun Vadeli Hedef<\/strong>: 30-45 $ (toplam %53-130 getiri)<br> - Bir\u00e7ok analist 30 $+ hedeflerde birle\u015fiyor<br> - <a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/SDGR\/forecast\/\">MarketBeat<\/a> 12 ayl\u0131k ortalama hedefi 27,83 $ olarak g\u00f6steriyor<br> - <a href=\"https:\/\/www.directorstalkinterviews.com\/schrodinger-inc-sdgr-stock-analysis-unpacking-a-potential-65-8-upside-with-strong-buy-ratings\/4121211716\">Director's Talk<\/a> ortalama hedefi 30,89 $ olarak belirtiyor<\/p> <p><strong>Sonu\u00e7<\/strong>: Biyoteknoloji volatilitesine tolerans\u0131 olan uzun vadeli b\u00fcy\u00fcme yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in AL.<\/p> <h2>Risk Analizi: Neler Yanl\u0131\u015f Gidebilir?<\/h2> <h3>Ba\u015fl\u0131ca Risk Fakt\u00f6rleri<\/h3> <ol> <li><strong>Mali S\u00fcrd\u00fcr\u00fclebilirlik<\/strong>: Negatif kazan\u00e7lar (-2,48 $ EPS) ve nakit ak\u0131\u015f\u0131 dikkatli izleme gerektirir<\/li> <li><strong>Y\u00fcksek Volatilite<\/strong>: %6,55 volatilite ve negatif Sharpe oranlar\u0131 tarihsel olarak k\u00f6t\u00fc risk-d\u00fczeltilmi\u015f getiriler g\u00f6steriyor<\/li> <li><strong>Sekt\u00f6r Duyarl\u0131l\u0131\u011f\u0131<\/strong>: Biyoteknoloji hisseleri genellikle temel g\u00f6stergelerden \u00e7ok sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131 ile hareket eder<\/li> <li><strong>Ar-Ge Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: Ba\u015far\u0131, ila\u00e7 ke\u015fif hatt\u0131n\u0131n sonu\u00e7 vermesine ba\u011fl\u0131d\u0131r<\/li> <li><strong>Rekabet<\/strong>: Hesaplamal\u0131 kimya \u015firketlerinin artan say\u0131s\u0131<\/li> <\/ol> <h3>2025 \u0130\u00e7in Pozitif Sinyaller<\/h3> <ol> <li><strong>G\u00fc\u00e7l\u00fc Ortakl\u0131klar<\/strong>: 150 milyon $ Novartis i\u015f birli\u011fi onay ve finansman sa\u011fl\u0131yor<\/li> <li><strong>Maliyet Y\u00f6netimi<\/strong>: %7 i\u015f g\u00fcc\u00fc azalt\u0131m\u0131 y\u0131ll\u0131k 30 milyon $ tasarruf bekleniyor<\/li> <li><strong>Gelir B\u00fcy\u00fcmesi<\/strong>: %10-15 yaz\u0131l\u0131m gelir b\u00fcy\u00fcmesi rehberli\u011finin s\u00fcrd\u00fcr\u00fclmesi<\/li> <li><strong>\u0130la\u00e7 Hatt\u0131 \u0130lerlemesi<\/strong>: \u00dc\u00e7 klinik a\u015fama onkoloji program\u0131 ilerliyor<\/li> <li><strong>Piyasa Konumu<\/strong>: 30+ y\u0131ll\u0131k Ar-Ge ile hesaplamal\u0131 ila\u00e7 ke\u015ffinde lider<\/li> <\/ol> <h2>Son 6 Ayda \u00d6nemli Haberler: Analiz<\/h2> <p>Schr\u00f6dinger, 2025 boyunca operasyonlar\u0131n\u0131 aktif \u015fekilde yeniden \u015fekillendiriyor:<\/p> <p><strong>A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 beklentileri a\u015ft\u0131; gelir (54,76M $ vs 52,03M $ beklenen) ve EPS (-0,59 $ vs -0,83 $ beklenen) pozitif s\u00fcrpriz yapt\u0131. \u015eirket, y\u0131ll\u0131k yaz\u0131l\u0131m gelir b\u00fcy\u00fcmesi rehberli\u011fini %10-15 aral\u0131\u011f\u0131nda tuttu.<\/p> <p><strong>Temmuz 2025<\/strong>: %7 stratejik i\u015f g\u00fcc\u00fc azalt\u0131m\u0131 duyuruldu, y\u0131ll\u0131k yakla\u015f\u0131k 30 milyon $ tasarruf bekleniyor. Bu maliyet optimizasyonu hamlesi, k\u00e2rl\u0131l\u0131k yoluna odaklanan analistler taraf\u0131ndan olumlu kar\u015f\u0131land\u0131.<\/p> <p><strong>Devam Ediyor<\/strong>: \u00dc\u00e7 klinik a\u015fama onkoloji program\u0131n\u0131n ilerlemesi s\u00fcr\u00fcyor, \u00f6zellikle MALT1 inhibit\u00f6r\u00fc SGR-1505 i\u00e7in Faz I verileri umut verici. \u015eirket ayr\u0131ca sanal kinaz panel teknolojisini beta olarak ba\u015flatt\u0131.<\/p> <p><strong>Ortakl\u0131k B\u00fcy\u00fcmesi<\/strong>: Eli Lilly ile i\u015f birli\u011fi geni\u015fletildi ve Ocak 2025'te ba\u015flayan 150 milyon $ Novartis ortakl\u0131\u011f\u0131 ilerlemeye devam ediyor.<\/p> <p>Traderlar i\u00e7in bu geli\u015fmeler, haber olaylar\u0131 etraf\u0131nda k\u0131sa vadeli ticaret f\u0131rsatlar\u0131 ve operasyonel iyile\u015ftirmelerle uzun vadeli yat\u0131r\u0131m tezinin g\u00fc\u00e7lenmesini sa\u011fl\u0131yor.<\/p> <h2>Yeni Ba\u015flayan Bir Trader Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015fla<\/strong>: Volatilite g\u00f6z \u00f6n\u00fcnde bulundurularak, dalgalanmalara dayanabilece\u011finiz bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Pozisyonunuzu tek seferde de\u011fil, birka\u00e7 hafta i\u00e7inde kademeli olarak olu\u015fturmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>12 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kur<\/strong>: 3. \u00e7eyrek kazan\u00e7 tarihini potansiyel giri\u015f f\u0131rsatlar\u0131 i\u00e7in i\u015faretleyin<\/li> <li><strong>Nakit Pozisyonunu \u0130zle<\/strong>: Nakit ak\u0131\u015f\u0131 g\u00f6stergelerindeki iyile\u015fmeler i\u00e7in \u00e7eyreklik raporlar\u0131 takip edin<\/li> <\/ol> <p>Esprili trader bilgeli\u011fi: \"SDGR ticareti yapmak, bilimsel bir deneyi izlemek gibidir - bazen beklenmedik \u015fekilde k\u00f6p\u00fcr\u00fcr, ama at\u0131l\u0131m beklemeye de\u011fer olabilir!\"<\/p> <h2>Ad\u0131m Ad\u0131m: Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Pratik \u0130pucu<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listeleri ve rekabet\u00e7i \u00fccretler sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td><td>Volatil hisselerde risk alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>G\u00fcncel fiyat\u0131 ara\u015ft\u0131r\u0131n<\/td><td>Ger\u00e7ek zamanl\u0131 fiyatlar\u0131 22 A\u011fustos 2025 itibar\u0131yla 19,58 $ olarak kontrol edin<\/td><\/tr> <tr><td>4<\/td><td>Limit emirleri kullan\u0131n<\/td><td>Volatilite s\u0131ras\u0131nda fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td><\/tr> <tr><td>5<\/td><td>Sipari\u015f detaylar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td><td>Hisse adedi, fiyat ve varsa komisyon \u00fccretlerini onaylay\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Al\u0131m\u0131 ger\u00e7ekle\u015ftirin<\/td><td>Ger\u00e7ekle\u015fen fiyat\u0131 limit emrinizle kar\u015f\u0131la\u015ft\u0131rarak izleyin<\/td><\/tr> <tr><td>7<\/td><td>Fiyat uyar\u0131lar\u0131 kurun<\/td><td>\u00d6nemli destek\/diren\u00e7 seviyeleri i\u00e7in bildirimler olu\u015fturun<\/td><\/tr> <tr><td>8<\/td><td>\u00c7\u0131k\u0131\u015f stratejinizi planlay\u0131n<\/td><td>K\u00e2r alma ve zarar durdurma seviyelerini \u00f6nceden belirleyin<\/td><\/tr> <\/tbody> <\/table> <h2>Yeni SDGR Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Pocket Option'un Cazibesi<\/h2> <p>Schr\u00f6dinger gibi yenilik\u00e7i \u015firketlere yat\u0131r\u0131m yapmak isteyenler i\u00e7in Pocket Option, b\u00fcy\u00fcme hissesi yat\u0131r\u0131m\u0131yla m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <p><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak, SDGR stratejilerini b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan test edebilirsiniz<\/p> <p><strong>H\u0131zl\u0131 Hesap Do\u011frulama<\/strong>: Tek bir belge ile 1 dakikal\u0131k KYC s\u00fcreci sayesinde f\u0131rsatlar ortaya \u00e7\u0131kt\u0131\u011f\u0131nda hemen i\u015flem yapmaya ba\u015flayabilirsiniz<\/p> <p><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: 100'den fazla para \u00e7ekme y\u00f6ntemi, ba\u015far\u0131l\u0131 SDGR i\u015flemlerinden elde etti\u011finiz k\u00e2rlar\u0131 tercih etti\u011finiz \u00f6deme kanal\u0131yla alman\u0131z\u0131 sa\u011flar<\/p> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, SDGR gibi volatil hisseleri takip etmeyi kolayla\u015ft\u0131r\u0131rken, d\u00fc\u015f\u00fck giri\u015f engeli biyoteknoloji yat\u0131r\u0131mlar\u0131 i\u00e7in uygun pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ayarlamaya olanak tan\u0131r.<\/p> <h2>2025'te Schr\u00f6dinger: Hesaplamal\u0131 \u0130la\u00e7 Ke\u015ffinde Lider<\/h2> <p>Schr\u00f6dinger, hesaplamal\u0131 kimya yoluyla ila\u00e7 ara\u015ft\u0131rmalar\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrmede \u00f6nc\u00fc konumdad\u0131r. \u015eirketin platformu, fizik tabanl\u0131 y\u00f6ntemleri makine \u00f6\u011frenimi ile birle\u015ftirerek ila\u00e7 ke\u015ffini h\u0131zland\u0131rmakta ve d\u00fcnya \u00e7ap\u0131nda b\u00fcy\u00fck ila\u00e7 \u015firketlerine hizmet vermektedir.<\/p> <p>1990 y\u0131l\u0131nda kurulan Schr\u00f6dinger, 30 y\u0131l\u0131 a\u015fk\u0131n Ar-Ge s\u00fcrecinde g\u00fc\u00e7l\u00fc bir fikri m\u00fclkiyet portf\u00f6y\u00fc olu\u015fturdu. \u015eirket, 15 k\u00fcresel lokasyonda yakla\u015f\u0131k 800 \u00e7al\u0131\u015fan istihdam etmekte ve molek\u00fcler sim\u00fclasyonda m\u00fcmk\u00fcn olan\u0131n s\u0131n\u0131rlar\u0131n\u0131 zorlamaya devam etmektedir.<\/p> <p><strong>2025 Y\u0131l\u0131 \u0130lgin\u00e7 Ger\u00e7e\u011fi<\/strong>: Schr\u00f6dinger'in hesaplamal\u0131 platformu, geleneksel olarak y\u0131llar s\u00fcren laboratuvar \u00e7al\u0131\u015fmalar\u0131n\u0131 aylar i\u00e7inde tamamlayarak yeni bir kanser ilac\u0131 aday\u0131n\u0131 rekor s\u00fcrede tan\u0131mlamaya yard\u0131mc\u0131 oldu - bu, teknolojilerinin d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc potansiyelini g\u00f6steriyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>Schr\u00f6dinger&#8217;in Mevcut Piyasa Konumunu Anlamak<\/h2>\n<p>22 A\u011fustos 2025 itibar\u0131yla Schr\u00f6dinger, Inc. (SDGR) hisseleri <strong>19,58 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor &#8211; bu, hem \u00f6nemli teknik g\u00f6stergelerin alt\u0131nda kritik bir fiyat noktas\u0131d\u0131r. Hisse senedi, 50 g\u00fcnl\u00fck hareketli ortalamas\u0131 olan 20,97 $ ve 200 g\u00fcnl\u00fck hareketli ortalamas\u0131 olan 21,82 $ seviyelerinin alt\u0131nda i\u015flem g\u00f6rerek ilgin\u00e7 bir kav\u015fakta bulunuyor.<\/p>\n<h3>Takip Edilmesi Gereken Kritik Kazan\u00e7 Tarihi<\/h3>\n<p>Takviminize <strong>12 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin &#8211; Schr\u00f6dinger&#8217;in 2025 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu \u00e7eyreklik a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur. Son kazan\u00e7lara bak\u0131ld\u0131\u011f\u0131nda:<\/p>\n<ul>\n<li><strong>6 A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 beklentileri a\u015ft\u0131; gelir 54,76 milyon $ (52,03 milyon $ tahminin \u00fczerinde) ve hisse ba\u015f\u0131na kazan\u00e7 (EPS) -0,59 $ (beklenen -0,83 $&#8217;dan daha iyi). Hisse senedi bu s\u00fcrpriz kazan\u00e7 sonras\u0131 pozitif ivme g\u00f6sterdi.<\/li>\n<li><strong>\u00d6nceki \u00e7eyrek<\/strong>: 2025 1. \u00e7eyrek gelir beklentiyi kar\u015f\u0131lad\u0131 ancak EPS beklentiyi kar\u015f\u0131lamad\u0131, bu da b\u00fcy\u00fcme a\u015famas\u0131ndaki biyoteknoloji \u015firketlerinde g\u00f6r\u00fclen volatiliteyi g\u00f6steriyor.<\/li>\n<\/ul>\n<p>Model, pozitif kazan\u00e7 s\u00fcrprizlerinin genellikle s\u00fcrd\u00fcr\u00fclebilir yukar\u0131 y\u00f6nl\u00fc ivme yaratt\u0131\u011f\u0131n\u0131, beklentilerin kar\u015f\u0131lanmamas\u0131n\u0131n ise k\u0131sa vadeli d\u00fczeltmeler ve ard\u0131ndan toparlanma ile sonu\u00e7land\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>Fiyat Performans Analizi: Son 6 Ay<\/h2>\n<p>Schr\u00f6dinger hisseleri son alt\u0131 ayda \u00f6nemli volatilite ya\u015fad\u0131; bu, hem piyasa duyarl\u0131l\u0131\u011f\u0131 de\u011fi\u015fimlerini hem de \u015firket \u00f6zelindeki geli\u015fmeleri yans\u0131t\u0131yor:<\/p>\n<table>\n<thead>\n<tr>\n<th>D\u00f6nem<\/th>\n<th>Fiyat Aral\u0131\u011f\u0131<\/th>\n<th>Temel Etkenler<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u015eubat-Mart 2025<\/td>\n<td>18-22 $<\/td>\n<td>4. \u00e7eyrek kazan\u00e7 sonras\u0131 iyimserlik<\/td>\n<\/tr>\n<tr>\n<td>Nisan-May\u0131s 2025<\/td>\n<td>17-20 $<\/td>\n<td>Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fc bask\u0131s\u0131<\/td>\n<\/tr>\n<tr>\n<td>Haziran-Temmuz 2025<\/td>\n<td>16-19 $<\/td>\n<td>Maliyet azaltma duyurular\u0131<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>17-20 $<\/td>\n<td>2. \u00e7eyrek kazan\u00e7 s\u00fcrprizi sonras\u0131 toparlanma<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Hisse senedi genel olarak 19 $ seviyesinde konsolidasyon g\u00f6sterdi, %6,55 volatilite orta d\u00fczey fiyat dalgalanmalar\u0131n\u0131 i\u015faret ediyor. Son bir ayda i\u015flem g\u00fcnlerinin sadece %47&#8217;si pozitif oldu, bu da temel iyile\u015fmelere ra\u011fmen temkinli yat\u0131r\u0131mc\u0131 duyarl\u0131l\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<h2>Ad\u0131m Ad\u0131m: SDGR&#8217;nin Yat\u0131r\u0131m Potansiyelini Analiz Etmek<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Mali durumu g\u00f6zden ge\u00e7ir<\/td>\n<td>Negatif EPS (-2,48) ancak g\u00fc\u00e7l\u00fc gelir b\u00fcy\u00fcmesi (+%15,7 Y\u0131ll\u0131k)<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>\u0130la\u00e7 geli\u015ftirme hatt\u0131n\u0131 de\u011ferlendir<\/td>\n<td>\u00dc\u00e7 klinik a\u015fama onkoloji program\u0131 ilerliyor<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Ortakl\u0131klar\u0131 takip et<\/td>\n<td>150 milyon $ Novartis i\u015f birli\u011fi onay sa\u011fl\u0131yor<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Nakit pozisyonunu izle<\/td>\n<td>Negatif nakit ak\u0131\u015f\u0131 dikkatli izleme gerektirir<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131n\u0131 g\u00f6zlemle<\/td>\n<td>Biyoteknoloji volatilitesi de\u011ferleme \u00e7arpanlar\u0131n\u0131 etkiler<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Kapsaml\u0131 analist de\u011ferlendirmeleri ve piyasa projeksiyonlar\u0131na dayanarak, beklenenler \u015funlard\u0131r:<\/p>\n<p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 21-23 $ aral\u0131\u011f\u0131 (mevcut fiyattan %7-17 art\u0131\u015f)<br \/> &#8211; %10-15 yaz\u0131l\u0131m gelir b\u00fcy\u00fcmesi rehberli\u011fi ile destekleniyor<br \/> &#8211; \u0130la\u00e7 hatt\u0131 ilerlemelerinden potansiyel kataliz\u00f6r<\/p>\n<p><strong>2026 Tahmini<\/strong>: 24-28 $ (y\u00fczde 22-43 b\u00fcy\u00fcme)<br \/> &#8211; Maliyet tasarruflar\u0131n\u0131n etkisiyle EPS&#8217;de iyile\u015fme bekleniyor<br \/> &#8211; Ek ortakl\u0131k duyurular\u0131 potansiyeli<\/p>\n<p><strong>2028 Projeksiyonu<\/strong>: 29-35 $ (y\u00fczde 48-79 de\u011fer art\u0131\u015f\u0131)<br \/> &#8211; Mevcut klinik programlar\u0131n olgunla\u015fmas\u0131<br \/> &#8211; Hesaplamal\u0131 ila\u00e7 ke\u015ffinde pazar pay\u0131n\u0131n geni\u015flemesi<\/p>\n<p><strong>2030 Uzun Vadeli Hedef<\/strong>: 30-45 $ (toplam %53-130 getiri)<br \/> &#8211; Bir\u00e7ok analist 30 $+ hedeflerde birle\u015fiyor<br \/> &#8211; <a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/SDGR\/forecast\/\">MarketBeat<\/a> 12 ayl\u0131k ortalama hedefi 27,83 $ olarak g\u00f6steriyor<br \/> &#8211; <a href=\"https:\/\/www.directorstalkinterviews.com\/schrodinger-inc-sdgr-stock-analysis-unpacking-a-potential-65-8-upside-with-strong-buy-ratings\/4121211716\">Director&#8217;s Talk<\/a> ortalama hedefi 30,89 $ olarak belirtiyor<\/p>\n<p><strong>Sonu\u00e7<\/strong>: Biyoteknoloji volatilitesine tolerans\u0131 olan uzun vadeli b\u00fcy\u00fcme yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in AL.<\/p>\n<h2>Risk Analizi: Neler Yanl\u0131\u015f Gidebilir?<\/h2>\n<h3>Ba\u015fl\u0131ca Risk Fakt\u00f6rleri<\/h3>\n<ol>\n<li><strong>Mali S\u00fcrd\u00fcr\u00fclebilirlik<\/strong>: Negatif kazan\u00e7lar (-2,48 $ EPS) ve nakit ak\u0131\u015f\u0131 dikkatli izleme gerektirir<\/li>\n<li><strong>Y\u00fcksek Volatilite<\/strong>: %6,55 volatilite ve negatif Sharpe oranlar\u0131 tarihsel olarak k\u00f6t\u00fc risk-d\u00fczeltilmi\u015f getiriler g\u00f6steriyor<\/li>\n<li><strong>Sekt\u00f6r Duyarl\u0131l\u0131\u011f\u0131<\/strong>: Biyoteknoloji hisseleri genellikle temel g\u00f6stergelerden \u00e7ok sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131 ile hareket eder<\/li>\n<li><strong>Ar-Ge Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: Ba\u015far\u0131, ila\u00e7 ke\u015fif hatt\u0131n\u0131n sonu\u00e7 vermesine ba\u011fl\u0131d\u0131r<\/li>\n<li><strong>Rekabet<\/strong>: Hesaplamal\u0131 kimya \u015firketlerinin artan say\u0131s\u0131<\/li>\n<\/ol>\n<h3>2025 \u0130\u00e7in Pozitif Sinyaller<\/h3>\n<ol>\n<li><strong>G\u00fc\u00e7l\u00fc Ortakl\u0131klar<\/strong>: 150 milyon $ Novartis i\u015f birli\u011fi onay ve finansman sa\u011fl\u0131yor<\/li>\n<li><strong>Maliyet Y\u00f6netimi<\/strong>: %7 i\u015f g\u00fcc\u00fc azalt\u0131m\u0131 y\u0131ll\u0131k 30 milyon $ tasarruf bekleniyor<\/li>\n<li><strong>Gelir B\u00fcy\u00fcmesi<\/strong>: %10-15 yaz\u0131l\u0131m gelir b\u00fcy\u00fcmesi rehberli\u011finin s\u00fcrd\u00fcr\u00fclmesi<\/li>\n<li><strong>\u0130la\u00e7 Hatt\u0131 \u0130lerlemesi<\/strong>: \u00dc\u00e7 klinik a\u015fama onkoloji program\u0131 ilerliyor<\/li>\n<li><strong>Piyasa Konumu<\/strong>: 30+ y\u0131ll\u0131k Ar-Ge ile hesaplamal\u0131 ila\u00e7 ke\u015ffinde lider<\/li>\n<\/ol>\n<h2>Son 6 Ayda \u00d6nemli Haberler: Analiz<\/h2>\n<p>Schr\u00f6dinger, 2025 boyunca operasyonlar\u0131n\u0131 aktif \u015fekilde yeniden \u015fekillendiriyor:<\/p>\n<p><strong>A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 beklentileri a\u015ft\u0131; gelir (54,76M $ vs 52,03M $ beklenen) ve EPS (-0,59 $ vs -0,83 $ beklenen) pozitif s\u00fcrpriz yapt\u0131. \u015eirket, y\u0131ll\u0131k yaz\u0131l\u0131m gelir b\u00fcy\u00fcmesi rehberli\u011fini %10-15 aral\u0131\u011f\u0131nda tuttu.<\/p>\n<p><strong>Temmuz 2025<\/strong>: %7 stratejik i\u015f g\u00fcc\u00fc azalt\u0131m\u0131 duyuruldu, y\u0131ll\u0131k yakla\u015f\u0131k 30 milyon $ tasarruf bekleniyor. Bu maliyet optimizasyonu hamlesi, k\u00e2rl\u0131l\u0131k yoluna odaklanan analistler taraf\u0131ndan olumlu kar\u015f\u0131land\u0131.<\/p>\n<p><strong>Devam Ediyor<\/strong>: \u00dc\u00e7 klinik a\u015fama onkoloji program\u0131n\u0131n ilerlemesi s\u00fcr\u00fcyor, \u00f6zellikle MALT1 inhibit\u00f6r\u00fc SGR-1505 i\u00e7in Faz I verileri umut verici. \u015eirket ayr\u0131ca sanal kinaz panel teknolojisini beta olarak ba\u015flatt\u0131.<\/p>\n<p><strong>Ortakl\u0131k B\u00fcy\u00fcmesi<\/strong>: Eli Lilly ile i\u015f birli\u011fi geni\u015fletildi ve Ocak 2025&#8217;te ba\u015flayan 150 milyon $ Novartis ortakl\u0131\u011f\u0131 ilerlemeye devam ediyor.<\/p>\n<p>Traderlar i\u00e7in bu geli\u015fmeler, haber olaylar\u0131 etraf\u0131nda k\u0131sa vadeli ticaret f\u0131rsatlar\u0131 ve operasyonel iyile\u015ftirmelerle uzun vadeli yat\u0131r\u0131m tezinin g\u00fc\u00e7lenmesini sa\u011fl\u0131yor.<\/p>\n<h2>Yeni Ba\u015flayan Bir Trader Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015fla<\/strong>: Volatilite g\u00f6z \u00f6n\u00fcnde bulundurularak, dalgalanmalara dayanabilece\u011finiz bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Pozisyonunuzu tek seferde de\u011fil, birka\u00e7 hafta i\u00e7inde kademeli olarak olu\u015fturmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>12 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kur<\/strong>: 3. \u00e7eyrek kazan\u00e7 tarihini potansiyel giri\u015f f\u0131rsatlar\u0131 i\u00e7in i\u015faretleyin<\/li>\n<li><strong>Nakit Pozisyonunu \u0130zle<\/strong>: Nakit ak\u0131\u015f\u0131 g\u00f6stergelerindeki iyile\u015fmeler i\u00e7in \u00e7eyreklik raporlar\u0131 takip edin<\/li>\n<\/ol>\n<p>Esprili trader bilgeli\u011fi: &#8220;SDGR ticareti yapmak, bilimsel bir deneyi izlemek gibidir &#8211; bazen beklenmedik \u015fekilde k\u00f6p\u00fcr\u00fcr, ama at\u0131l\u0131m beklemeye de\u011fer olabilir!&#8221;<\/p>\n<h2>Ad\u0131m Ad\u0131m: Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Pratik \u0130pucu<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve rekabet\u00e7i \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>Volatil hisselerde risk alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>G\u00fcncel fiyat\u0131 ara\u015ft\u0131r\u0131n<\/td>\n<td>Ger\u00e7ek zamanl\u0131 fiyatlar\u0131 22 A\u011fustos 2025 itibar\u0131yla 19,58 $ olarak kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit emirleri kullan\u0131n<\/td>\n<td>Volatilite s\u0131ras\u0131nda fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sipari\u015f detaylar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td>\n<td>Hisse adedi, fiyat ve varsa komisyon \u00fccretlerini onaylay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Al\u0131m\u0131 ger\u00e7ekle\u015ftirin<\/td>\n<td>Ger\u00e7ekle\u015fen fiyat\u0131 limit emrinizle kar\u015f\u0131la\u015ft\u0131rarak izleyin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun<\/td>\n<td>\u00d6nemli destek\/diren\u00e7 seviyeleri i\u00e7in bildirimler olu\u015fturun<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>\u00c7\u0131k\u0131\u015f stratejinizi planlay\u0131n<\/td>\n<td>K\u00e2r alma ve zarar durdurma seviyelerini \u00f6nceden belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Yeni SDGR Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Pocket Option&#8217;un Cazibesi<\/h2>\n<p>Schr\u00f6dinger gibi yenilik\u00e7i \u015firketlere yat\u0131r\u0131m yapmak isteyenler i\u00e7in Pocket Option, b\u00fcy\u00fcme hissesi yat\u0131r\u0131m\u0131yla m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<p><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak, SDGR stratejilerini b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan test edebilirsiniz<\/p>\n<p><strong>H\u0131zl\u0131 Hesap Do\u011frulama<\/strong>: Tek bir belge ile 1 dakikal\u0131k KYC s\u00fcreci sayesinde f\u0131rsatlar ortaya \u00e7\u0131kt\u0131\u011f\u0131nda hemen i\u015flem yapmaya ba\u015flayabilirsiniz<\/p>\n<p><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: 100&#8217;den fazla para \u00e7ekme y\u00f6ntemi, ba\u015far\u0131l\u0131 SDGR i\u015flemlerinden elde etti\u011finiz k\u00e2rlar\u0131 tercih etti\u011finiz \u00f6deme kanal\u0131yla alman\u0131z\u0131 sa\u011flar<\/p>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, SDGR gibi volatil hisseleri takip etmeyi kolayla\u015ft\u0131r\u0131rken, d\u00fc\u015f\u00fck giri\u015f engeli biyoteknoloji yat\u0131r\u0131mlar\u0131 i\u00e7in uygun pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ayarlamaya olanak tan\u0131r.<\/p>\n<h2>2025&#8217;te Schr\u00f6dinger: Hesaplamal\u0131 \u0130la\u00e7 Ke\u015ffinde Lider<\/h2>\n<p>Schr\u00f6dinger, hesaplamal\u0131 kimya yoluyla ila\u00e7 ara\u015ft\u0131rmalar\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrmede \u00f6nc\u00fc konumdad\u0131r. \u015eirketin platformu, fizik tabanl\u0131 y\u00f6ntemleri makine \u00f6\u011frenimi ile birle\u015ftirerek ila\u00e7 ke\u015ffini h\u0131zland\u0131rmakta ve d\u00fcnya \u00e7ap\u0131nda b\u00fcy\u00fck ila\u00e7 \u015firketlerine hizmet vermektedir.<\/p>\n<p>1990 y\u0131l\u0131nda kurulan Schr\u00f6dinger, 30 y\u0131l\u0131 a\u015fk\u0131n Ar-Ge s\u00fcrecinde g\u00fc\u00e7l\u00fc bir fikri m\u00fclkiyet portf\u00f6y\u00fc olu\u015fturdu. \u015eirket, 15 k\u00fcresel lokasyonda yakla\u015f\u0131k 800 \u00e7al\u0131\u015fan istihdam etmekte ve molek\u00fcler sim\u00fclasyonda m\u00fcmk\u00fcn olan\u0131n s\u0131n\u0131rlar\u0131n\u0131 zorlamaya devam etmektedir.<\/p>\n<p><strong>2025 Y\u0131l\u0131 \u0130lgin\u00e7 Ger\u00e7e\u011fi<\/strong>: Schr\u00f6dinger&#8217;in hesaplamal\u0131 platformu, geleneksel olarak y\u0131llar s\u00fcren laboratuvar \u00e7al\u0131\u015fmalar\u0131n\u0131 aylar i\u00e7inde tamamlayarak yeni bir kanser ilac\u0131 aday\u0131n\u0131 rekor s\u00fcrede tan\u0131mlamaya yard\u0131mc\u0131 oldu &#8211; bu, teknolojilerinin d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc potansiyelini g\u00f6steriyor.<\/p>\n"},"faq":[{"question":"Schr\u00f6dinger, Inc. hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 a\u00e7\u0131p fonlay\u0131n, g\u00fcncel fiyat\u0131 kontrol edin, limit emirleri kullanarak al\u0131m yap\u0131n ve i\u015flem detaylar\u0131n\u0131 dikkatlice g\u00f6zden ge\u00e7irin."},{"question":"Schr\u00f6dinger'in 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 21-23 $ aral\u0131\u011f\u0131, 2026'da 24-28 $, 2028'de 29-35 $ ve 2030'da 30-45 $ aral\u0131\u011f\u0131nda fiyat hedefleri \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Schr\u00f6dinger hisselerinin riskleri nelerdir?","answer":"Negatif kazan\u00e7lar, y\u00fcksek volatilite, sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131, Ar-Ge ba\u011f\u0131ml\u0131l\u0131\u011f\u0131 ve artan rekabet ba\u015fl\u0131ca risk fakt\u00f6rleridir."},{"question":"Yeni ba\u015flayanlar Schr\u00f6dinger hisseleri i\u00e7in ne yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, \u00f6nemli kazan\u00e7 tarihleri i\u00e7in uyar\u0131lar kurun ve nakit pozisyonunu d\u00fczenli takip edin."},{"question":"Pocket Option neden Schr\u00f6dinger yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 hesap do\u011frulama ve \u00e7ok say\u0131da para \u00e7ekme se\u00e7ene\u011fi sunarak b\u00fcy\u00fcme hisselerine yat\u0131r\u0131m yapmay\u0131 kolayla\u015ft\u0131r\u0131r."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Schr\u00f6dinger, Inc. hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 a\u00e7\u0131p fonlay\u0131n, g\u00fcncel fiyat\u0131 kontrol edin, limit emirleri kullanarak al\u0131m yap\u0131n ve i\u015flem detaylar\u0131n\u0131 dikkatlice g\u00f6zden ge\u00e7irin."},{"question":"Schr\u00f6dinger'in 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 21-23 $ aral\u0131\u011f\u0131, 2026'da 24-28 $, 2028'de 29-35 $ ve 2030'da 30-45 $ aral\u0131\u011f\u0131nda fiyat hedefleri \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Schr\u00f6dinger hisselerinin riskleri nelerdir?","answer":"Negatif kazan\u00e7lar, y\u00fcksek volatilite, sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131, Ar-Ge ba\u011f\u0131ml\u0131l\u0131\u011f\u0131 ve artan rekabet ba\u015fl\u0131ca risk fakt\u00f6rleridir."},{"question":"Yeni ba\u015flayanlar Schr\u00f6dinger hisseleri i\u00e7in ne yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, \u00f6nemli kazan\u00e7 tarihleri i\u00e7in uyar\u0131lar kurun ve nakit pozisyonunu d\u00fczenli takip edin."},{"question":"Pocket Option neden Schr\u00f6dinger yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 hesap do\u011frulama ve \u00e7ok say\u0131da para \u00e7ekme se\u00e7ene\u011fi sunarak b\u00fcy\u00fcme hisselerine yat\u0131r\u0131m yapmay\u0131 kolayla\u015ft\u0131r\u0131r."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-22T11:28:03+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-22T11:28:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/\",\"name\":\"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"datePublished\":\"2025-08-22T11:28:03+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/","og_locale":"tr_TR","og_type":"article","og_title":"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-22T11:28:03+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-22T11:28:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/","name":"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","datePublished":"2025-08-22T11:28:03+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-schrdinger\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Schr\u00f6dinger, Inc. (SDGR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Schr\u00f6dinger, Inc. (SDGR) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":343230,"slug":"how-to-buy-schrdinger","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Schr\u00f6dinger, Inc. (SDGR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Schr\u00f6dinger, Inc. (SDGR)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-schrdinger\/"},"pt_AA":{"locale":"pt_AA","id":343227,"slug":"how-to-buy-schrdinger","post_title":"Como comprar a\u00e7\u00f5es da Schr\u00f6dinger, Inc. (SDGR) - Investimento em a\u00e7\u00f5es da Schr\u00f6dinger, Inc. (SDGR)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-schrdinger\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/343231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=343231"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/343231\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334027"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=343231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=343231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=343231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}